- Investor Relations Asia Pacific

WuXi Biologics (Cayman) Inc.
(Incorporated in the Cayman Islands with limited liability)

Press Releases       

Please download the latest "Acrobat Reader" to view the PDF.

  • 2018-November-29
  • WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018 (in PDF)
  • 2018-August-20
  • Wuxi Biologics Reports Robust 2018 Interim Results Revenue up 61.2% to a Record High of RMB1,054.4 Million, Net Profit 270.7% of Same Period Last Year to RMB249.6 Million Diluted EPS 211.1% of Same Period Last Year, Commenced Commercial Production Of "Trogarzotm" Total Integrated Projects Increased To 187 Including 10 Late-Phase Projects, Phenomenal Growth in Total Backlog to US$1,782 Million Global Expansion will Bring the Total Capacity to Approximately 220,000L (in PDF)
  • 2018-March-19
  • WuXi Biologics Reports Remarkable 2017 Annual Results Revenue Up 63.7% to a Record High of RMB1,618.8 Million Adjusted Net Profit Up 85.1% to RMB408.1 Million Gross Profit Margin, Net Profit Margin and Adjusted Net Profit Margin All Increased Significantly (in PDF)
  • 2018-March-1
  • Press Release (Chinese Version) (in PDF)
  • 2018-February-8
  • Press Release (Chinese Version) (in PDF)
  • 2018-January-19
  • Press Release (Chinese Version) (in PDF)
  • 2018-January-9
  • WuXi Biologics Receives Best IPO Award and Best Investor Relations Award 2017 (in PDF)
  • 2017
  • 2017 Press Releases

  • Company's Index

  • About   |   Terms of Use   |   Disclaimer
    © Copyright 1996-2018 Ltd. All rights reserved.
    DISCLAIMER: Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall Ltd. be liable for damages resulting from the use of the information provided on this website.